Diese Veranstaltung hat bereits stattgefunden


18th EURETINA Congress

European Society Congress of Retina Specialists 2018
1020 Wien, Österreich
Veranstaltungsnummer: 26991
Zertifizierung: genehmigt
CME Max: 27
Gebühren ab: 150,00 EUR
verfügbare Plätze: unbegrenzt
Sprache: Englisch

 Zum Kalender hinzufügen
  • Datum
    20.09.2018, 09:00 - 23.09.2018, 13:30
    The 18th EURETINA Congress will be held in Vienna, Austria. The scientific program will comprise a variety of symposia, poster sessions, instructional and surgical courses, video and free paper presentations and several satellite meetings. The main topics of this conference are ocular oncology for surgical and medical retina specialists, novelties and late breaking developments in retina and technology, AMD and evidence based treatment in the AntiVEGF Era.


    Teilnehmer max.

    Gebühren ab
    400,00 EUR

    Earlybird bis 20.09.2018
    350,00 EUR
    EURETINA Member:
    Before 20 Sept - 350 €
    20-23 Sept - 400 €

    Before 20 Sept - 450 €
    20-23 Sept - 500 €

    Healthcare Professional:
    Before 20 Sept - 175 €
    20-23 Sept - 225 €

    Ärzte/-innen in Weiterbildung

    Teilnehmer max.

    Gebühren ab
    240,00 EUR

    Earlybird bis 20.09.2018
    190,00 EUR
    Trainee/ Resident Member:
    Before 20 Sept - 190 €
    20-23 Sept - 240 €

    Trainee/Resident Non-Member:
    Before 20 Sept - 210 €
    20-23 Sept - 260 €

    medizinisches Fachpersonal

    Teilnehmer max.

    Gebühren ab
    200,00 EUR

    Earlybird bis 20.09.2018
    150,00 EUR


    Teilnehmer max.

    Gebühren ab
    1.500,00 EUR

    Earlybird bis 20.09.2018
    1.300,00 EUR
  •    Thursday 20th September, 2018  
       EURETINA Main Session 1:
    Ocular Oncology for surgical and medical retina specialists
    09:00 - 10:30 Introduction S. Seregard
      How modern imaging can aid in the differential diagnosis of small intraocular tumours H. Heimann
      Intravitreal treatment of radiation -  and tumor - associated macular edema L. Zografos
      How to diagnose intraocular lymphoma - clinical presentation and biopsy techniques N. Bornfeld
      Surgical resection as an alternative to enucleation in large uveal melanoma - risks and benefits N. Bechrakis
      Prediction of metastatic disease in patients with uveal melanoma and screening recommendations B. Damato
      Critical bevaluation of systemic, intracameral and opthalmic artery chemotherapy for retinoblastoma M. Sagoo
       EURETINA Main Session 2:
    The EURETINA guidelines for management of retinal disease
    11:00 - 12:30 Where is anti-VEGF therapy now: achievements and challenges  
      Neovascular AMD: the ten key messages U. Schmidt-Erfurth
      Diabetic macular edema the ten key messages  F. Bandello
      Vein occlusion: the ten key messages A. Loewenstein
      A state-of-the-art in endophthalmitis in anti-VEGF therapy A. Grzybowski
      The future needs and progress in anti-VEGF therapy D. Martin
      End of session  
       EURETINA Main Session 3:
    Decision making in challenging cases
    14:30 - 16:00 Should we treat subclinical CNV discovered by OCTA? S. Schmitz-Valckenberg
      Is it valuable to tolerate subretinal fluid in the treatment of type 1 CNV? A. Tufail
      If a PDR associated with DME is treated by anti-VEGF, is it safe to space out injections? R. Silva
      Do you stop anti-VEGFs in persistent RVO related CME without binocular problems? JR. Vingerling
      Should we operate early myopic foveoschisis to avoid complications? Y. Ikuno
      Can we expect visual improvement in some lamellar macular hole after surgery? R. Schumann
      What to do in chronic CSCR when serous retinal detachment reccurs after PDT? C. Boon
      How to manage Coat's disease with central macular lipid exudation? A. Daruich-Matet
      End of session  
       Friday 21st September, 2018  
       EURETINA Main Session 4:
    Novelties and late breaking developments in
    Retina & Technology
    8:00 - 9:30 Recent advances in surgical techniques: new trends and expectations  
      AI-based analysis: A revolution in imaging  
      Genetic therapy: reinventing genes  
      Novel understanding of normal and abnormal retinal vascularization under the light of new imagery  
      Late Breaking Presentations  
      End of session  
       EURETINA Main Session 5: AMD  
    12:00 - 13:30 Dry AMD - how to proceed? Current management of exudative AMD F. Holz
      New studies in exudative AMD P. Dugel
      When can we define a patient as a non-responder A. Loewenstein
      Long-term effects of anti-VEGF M. Goldstein
      Biomarkers on CNV M. Battaglia Parodi
      Guts, genes and AMD M. Zinkernagel
       Saturday 22nd September, 2018  
       EURETINA Main Session 6:PDR in 2018:
    Evidence based treatment in the AntiVEGF Era
    8:00 - 9:30 Pathophysiology of macular edema, diabetic and other M. Larsen
      Retinal photocoagulation : Pro and Cons E. Pilotto
      Anti VEGF and proliferative diabetic retinopathy trial data:  S. Sivaprasad / J. Wells
      How might Protocol S and Clarity results be generalized in current practice R. Schlingemann
      Cost effectiveness of antiVEGF therapy for PDR  N. Bressler
      Vitrectomy in PDR 2018 D. Steel

    Chaired panel discussion on pragmatic evidence based management of PDR

    in 2018 (specific scenarios): 

      i.    Severe NPDR, treat don’t treat?  
      ii.    Low risk NVD/E treat don’t treat: what with?   
      iii.    HRC: no macular edema   
      iv.    HRC: with macular edema  
      v.    Persistent NV after standard PRP  
      vi.    Mild vitreous haemorrhage after full PRP  
      vii.    Florid PDR with no previous treatment   
      End of session  
       EURETINA Main Session 7: Imaging  
    16:30 Agreement between OCT angiography and FA/ICG in neovascular AMD U. Chakravarthy
      Single layer OCT, OCT angiography and fuctional correlates in diabetic patients E. Midena
      Retinal vascular biomakers forAlzheimer's disease T. Peto
      Adaptive optics-SLO single photoreceptor imaging and Psychophysics W. Harmening
      The use of artificial intelligence / deep learning in the analysis of retinal images P. Keane
      Full volume render virtual reality OCT P. Maloca
      End of session  
       EURETINA Main Session 8: Research Session  
    11:00 - 12:30 Genetics in retinal disease B. LeRoy
      Genetics in retinal disease C.C.W. Klaver
      Gene therapy achromatopsia CNGA3 D. Fischer
      Gene therapy achromatopsia CNGB3 J. Bainbridge
      Optogenetics for end-stage retinis pigmentosa (2 perspectives)
    Cell therapy for age-related macular degeneration
    S. Kleinlogel
      Gene therapy for retinis pigmentosa R. MacLaren
      The Argus II retinal implant for retinis pigmentosa S. Rizzo
      The AMS epiretinal implant for retinis pigmentosa F. Gekeler
      End of session  
       Sunday 23 September, 2018  
       EURETINA Main Session 9: Vitreoretinal surgery  
    10:00 - 11:30 Retinal detachment outcomes in IRIS (Intelligent research in sight)
    Intraocular foreign body removal: Tips and tricks
      Paediatric retinal detachment S. Chien Wong
      Surgical management of optic pit maculopathy: Which is the best technique? J. Garcia Arumi
      Endoillumination buckle  
      Retinopathy of prematurity  
       EURETINA Main Session 10: Myopia - a full update  
    12:00 - 13:30 Genetics, risk factors and epidemiology of myopia C.C.W. Klawer
      Progression of myopia and myopic maculopathy J. Jonas
      Prevention of myopia and of ist evolution  G. Cheung
      Refractive and lens surgery in highly myopic eyes and lens from the retina perspective  A. Grzybowski
      Modern imaging of the retina in high myopia Y. lida
      Domeshape macula news  
      Myopic choroidal neovascularization management update G. Querques
      Update on modern surgery in highly myopic eyes to achieve best possible results R. Tadayoni
      New technics for closing myopic macular holes M. Figueroa


    Meet the Experts, OD-OS Navilas® Booth C207

    Friday, September 21st 2018

    10:00 am - D. Maltsev - Macroaneurysms


    Saturday, September 22nd 2018

    10:00 am - J. Chhablani - MSP vs. PDT for CSCR

    13:30 pm - I. Kozak - Coat's Disease



    Sunday, September 23rd 2018

    10:00 am - F. Amorosa - The future of PRP Treatment



  • Reed Messe Wien

    Temple House
    Temple Road, Blackrock
    Tel.: +353 (0)1 210 0092
    Fax: +353 (0)1 209 1112


    Please contact the organizer for further information.